Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Anavex Life Sciences Corp. (AVXL) had Non-Operating Income/Expense of $8.26M for the most recently reported fiscal year, ending 2023-09-30.
Income Statement Financials | |
-- |
|
$-47.51M |
|
-- |
|
-- |
|
$55.76M |
|
$-55.76M |
|
Non-Operating Income/Expense |
$8.26M |
$-47.50M |
|
$-47.50M |
|
$-47.51M |
|
$-47.51M |
|
$-47.51M |
|
$-47.51M |
|
$-55.76M |
|
$-55.76M |
|
79.79M |
|
79.79M |
|
$-0.60 |
|
$-0.60 |
|
Balance Sheet Financials | |
$154.39M |
|
-- |
|
-- |
|
$154.39M |
|
$12.53M |
|
-- |
|
-- |
|
$12.53M |
|
$141.85M |
|
$141.85M |
|
$141.85M |
|
82.07M |
|
Cash Flow Statement Financials | |
$-27.79M |
|
-- |
|
$29.65M |
|
$149.16M |
|
$151.02M |
|
$1.87M |
|
$16.37M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
12.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-27.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.49% |
|
-33.49% |
|
-30.77% |
|
-33.49% |
|
$1.73 |
|
$-0.35 |
|
$-0.35 |